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ABSTRACT
How the infection risks compare after umbilical cord blood (UCB) and bone marrow (BM) transplantation is
not known. Therefore, we compared serious infections in the 2 years after pediatric myeloablative unrelated
donor transplantation with unmanipulated BM (n  52), T cell–depleted (TCD) BM (n  24), or UCB (n 
60) for the treatment of hematologic malignancy. Overall, the cumulative incidence of 1 or more serious
infections was comparable between groups (BM, 81%; TCD, 83%; UCB, 90%; P  .12). Furthermore, by
taking all serious infections into account and using multivariate techniques with unmanipulated BM as the
reference, there were also no significant differences between groups (TCD relative risk [RR], 1.6; P  .10;
UCB RR, 1.0; P  .84). Within the time periods days 0 to 42, days 43 to 100, and days 101 to 180, the only
difference was a greater risk of viral infections from days 0 to 42 in TCD recipients (RR, 3.5; P .02). Notably,
after day 180, TCD recipients had a significantly increased infection risk (RR, 3.1; P  .03), whereas the risk
in UCB recipients (RR, 0.5; P  .23) was comparable to that in BM recipients. Other factors associated with
an increased infection risk in the 2 years after transplantation were age>8 years, graft failure, and severe acute
graft-versus-host disease. These data suggest that the risk of serious infection after pediatric UCB transplan-
tation is comparable to that with unmanipulated BM.
© 2005 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Serious infection is the most common problem
fter unrelated donor (URD) transplantation and ac-
ounts for substantial morbidity and mortality. Ochs
t al. [1] analyzed the effect of late infections (50 days
o 2 years) in 98 URD bone marrow (BM) and 151
elated donor transplant recipients and found that late
nfection was the dominant independent factor asso-
iated with increased transplant-related mortality and
onsequent inferior survival in URD recipients. How-
ver, relatively few studies have conducted a detailed
nalysis of the infectious complications after URD
ransplantation or investigated how different URD
ematopoietic stem cell (HSC) sources affect infec-
ion risk. c
62This question is of even greater relevance given
he increasing use of umbilical cord blood (UCB) as an
lternative HSC source, [2-6] because the HLA dis-
arity, the potential for delayed neutrophil recovery,
nd the naive neonatal immune system could all be
xpected to contribute to an increased risk of both
arly and late infectious complications after UCB
ransplantation (UCBT) as compared with that seen
fter BM transplantation (BMT). However, UCBT
ecipients may be at an advantage because of the
ecreased incidence and severity of graft-versus-host
isease (GVHD) [2-6] and the consequent decreased
xposure to immunosuppression. To investigate how
he infection risks after UCBT and BMT compare, we
onducted a comparison of serious infections in the 2
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Serious Infections after Unrelated Donor Transplantation
Bears after transplantation in children who received
nmanipulated BM, BM with T-cell depletion (TCD),
r UCB for the treatment of hematologic malignancy.
ATIENTS AND METHODS
election of URD HSC Source
All pediatric patients undergoing a ﬁrst transplan-
ation at the University of Minnesota for the treat-
ent of hematologic malignancy between 1994 and
002 were analyzed. During this period, patients with-
ut 5/6 or 6/6 HLA-matched related donors were
ligible for URD BMT if a 5/6 or 6/6 HLA-A, -B, and
DRB1 matched volunteer donor was available. URD
ransplantation candidates were offered TCD versus
nmanipulated BM according to the current institu-
ional study available at the time. Between 1995 and
000, all patients were invited to participate in the
ational TCD trial. If patients refused this study,
hen they received unmanipulated BM. TCD was per-
ormed by counterﬂow elutriation, as previously de-
able 1. Patient and Graft Characteristics
Variable BM (n  52)
ge (y)* 8 (0.6-18)
eight (kg)* 27 (6-95)
ale 36 (69%)
ecipient CMV 20 (38%)
ays to Tx* 520 (118-4465)
iagnosis
ALL 30 (58%)
CR1 8
CR2 21
Relapse 1
AML 16 (31%)
CR1 4
CR2 8
Relapse 4
MDS 6 (12%)
NHL 0
onditioning
Cy/TBI 52 (100%)
Bu/Cy 0
Bu/melphalan 0
VHD prophylaxis
MTX/CSA 51 (98%)
CSA/MP 0
MTX/FK506 1 (2%)
ransplantation year
1994-1998 42 (81%)
1999-2002 10 (19%)
Follow-up(y)* 5.7 (1.0-9.2)
nfused TNC dose (108)* 2.00 (1.06-3.00)
LA-A, -B, and -DRB1 match
6/6 30 (58%)
5/6 20 (38%)
4/6 2 (4%)
MV indicates cytomegalovirus; Tx, transplantation; ALL, acute ly
leukemia; MDS, myelodysplasia; NHL, non-Hodgkin lymphom
methotrexate; CSA, cyclosporine A; MP, methylprednisolone; T
Median/range.cribed [7], which resulted in a ﬁxed CD3 cell dose of p
B&MT 105/kg. Patients were eligible for UCBT if no
uitably matched URD was available or if transplan-
ation was required urgently. After the closure of the
ational TCD study, patients were offered UCB or
nmanipulated BM. Transplantation protocols for the
reatment of all patients, including the subsequent
nalysis of transplant outcomes and complications,
ere approved by the institutional review board, and
ritten informed consent was obtained from all pa-
ients and/or their guardians.
atient Characteristics
One hundred thirty-six consecutive patients aged
to 18 years underwent transplantation with unma-
ipulated BM (n  52), BM with TCD (n  24), or
CB (n  60). Patient characteristics are summarized
n Table 1. The median patient age was 8 years (range,
.5-18 years). Age, weight, sex, seropositivity for cy-
omegalovirus (CMV), time from diagnosis to trans-
lantation, and diagnoses were similar among the 3
TCD (n  24) UCB (n  60) P Value
10 (0.5-17) 8 (0.5-18) .46
30 (6-95) 29 (6-91) .32
15 (63%) 37 (62%) .68
12 (50%) 27 (45%) .61
588 (111-4832) 409 (73-4452) .66
>.80
16 (67%) 31 (52%)
4 6
11 22
1 3
7 (29%) 26 (43%)
0 5
5 15
2 6
1 (4%) 1 (2%)
0 2 (3%)
>.80
24 (100%) 55 (92%)
0 2 (3%)
0 3 (3%)
<.01
0 0
24 (100%) 60 (100%)
0 0
<.01
22 (92%) 20 (33%)
2 (8%) 40 (67%)
5.7 (3.0-8.1) 1.3 (0.7-7.0) <.01
.43 (0.11-2.02) 0.35 (0.13-1.34) <.01
<.01
16 (67%) 10 (17%)
7 (29%) 21 (35%)
1 (4%) 29 (48%)
lastic leukemia; CR, complete remission; AML, acute myelogenous
yclophosphamide; TBI, total body irradiation; Bu, busulfan; MTX,
otal nucleated cell.0
mphob
a; Cy, c
NC, tatient groups.
363
U
(
c
T
g
m
d
p
d
C
o
(
1
d
m
1
3
(
G
T
s
r
d
r
o
t
c
H
o
S
t
s
n
2
r
f
w
s
t
r
p
t
p
t
p
w
p
T
t
n
1
t
f
k
l
a
c
C
g
i
f
1
M
B
M
a
i
t
i
c
w
t
e
c
s
i
i
i
i
a
A
v
4
l
m
c
t
d
c
u
i
s
f
p
t
i
c
t
s
J. N. Barker et al.
3All patients received myeloablative conditioning.
nmanipulated BM recipients received methotrexate
15 mg/m2 day 1 and 10 mg/m2 days 3, 6, and 11) and
yclosporin A (CSA) as GVHD prophylaxis, whereas
CD and UCB recipients received antithymocyte
lobulin (ATGAM; Pharmacia, Kalamazoo, MI) 15
g/kg days 3 to 1 every 12 hours for 6 doses
uring conditioning in addition to CSA and methyl-
rednisone (1 mg/kg intravenously every 12 hours on
ays 5 to 19 with a rapid taper thereafter). Dosing of
SA was similar in all patients (day3 for a minimum
f 6 months).
A greater proportion of BM (81%) and TCD
92%) recipients underwent transplantation between
994 and 1998, whereas 67% of UCB recipients un-
erwent transplantation between 1999 and 2002. The
edian follow-up of survivors was 5.7 years (range,
.0-9.2 years) for BM recipients, 5.7 years (range,
.0-8.1 years) for TCD recipients, and 1.3 years
range, 0.7-7.0 years) for UCB recipients (P  .01).
raft Characteristics
All UCB grafts consisted of single units. UCB and
CD recipients received grafts with a signiﬁcantly
maller nucleated cell dose than unmanipulated BM
ecipients (P  .01; Table 1). Although all volunteer
onors were chosen to be at least 5/6 matched to the
ecipient, upon introduction of HLA-DRB1 allele res-
lution typing in 1995, retrospective typing revealed
hat 2 unmanipulated BM recipients and 1 TCD re-
ipient received 4/6 matched grafts. Grafts were 6/6
LA-A, -B, and -DRB1 matched in 58% of BM, 67%
f TCD, and 17% of UCB recipients (P  .01).
upportive Care
All patients were hospitalized in single rooms ven-
ilated with a high-efﬁciency particulate air ﬁltration
ystem. First-line bacterial prophylaxis during afebrile
eutropenia was penicillin and ciproﬂoxacin until
002, when it was switched to gatiﬂoxacin. All patients
eceived ﬂuconazole for prophylaxis of yeast infections
or 100 days, trimethoprim-sulfamethoxazole twice
eekly for prophylaxis of pneumocystis pneumonia
tarting after engraftment for at least 12 months after
ransplantation, and penicillin, a macrolide, or a ﬂuo-
oquinolone for prophylaxis of encapsulated gram-
ositive organisms during treatment of GVHD. Pa-
ients seropositive for herpes simplex virus received
rophylactic low-dose intravenous acyclovir during
he ﬁrst month after transplantation. Standard pro-
hylaxis for patients seropositive for CMV or those
ith a seropositive donor was high-dose acyclovir. As
art of an institutional study, 5 patients (4 BM and 1
CD) received prophylactic ganciclovir during cy-oreduction followed by high-dose acyclovir until t
64eutrophil recovery and then ganciclovir until day
00. CMV antigenemia testing was performed rou-
inely from 1996 on.
Broad-spectrum antibiotics were administered for
ebrile neutropenia, and amphotericin B 0.3 to 1.2 mg/
g/d was added for persistent fever unresponsive to at
east 72 hours of antibacterial antibiotics. Liposomal
mphotericin was substituted for generic amphoteri-
in as necessary per formulary criteria. Documented
MV infection or disease was treated per institutional
uidelines. From 1997, granulocyte-colony stimulat-
ng factor (5 g/kg/d) was administered to all patients
rom day 0 until the neutrophil count was 2.5 
09/L for at least 2 consecutive days.
ethod of Infection Data Collection
Infection data were collected prospectively by the
iostatistical Support Group of the University of
innesota and then audited for completeness and
ccuracy by retrospective review of the outpatient and
npatient records of all patients. For the purposes of
his study, an infection episode was deﬁned as any
nfection conﬁrmed by culture, histology, polymerase
hain reaction, or antigenemia for which treatment
as initiated. Dermatomal varicella-zoster reactiva-
ion virus and sinusitis or pneumonia with radiologic
vidence of infection did not require microbiologic
onﬁrmation to be documented as an infectious epi-
ode. Otherwise-uncomplicated fever of unknown or-
gin was excluded because of the potential for report-
ng bias. Adenovirus and polyomavirus (BK virus)
nfections were documented when a compatible clin-
cal picture was supported by recovery of the virus in
diagnostic specimen from a contiguous body site.
vailable diagnostic methods for adenovirus included
iral tube culture or rapid antigen testing (serogroups
0 and 41 only), whereas polyomavirus infection was
imited to an in-house semiquantitative urine poly-
erase chain reaction assay, urine cytology for decoy
ells, or characteristic changes on genitourinary his-
opathology specimens.
Only serious infections were analyzed. These were
eﬁned as infections associated with death or severe
linical compromise and included shock or organ fail-
re, CMV end-organ disease, lower respiratory tract
nfection with respiratory viruses, invasive molds in
inus or lung, or disseminated Aspergillus species. In-
ections requiring any intravenous treatment or hos-
italization, including asymptomatic CMV reactiva-
ion treated with intravenous ganciclovir and catheter
nfections requiring intravenous antibiotics, were also
lassiﬁed as serious infections. However, mild infec-
ions not requiring therapy or infections of moderate
everity requiring only oral antibiotics on an outpa-
ient basis were excluded from the analysis.
i
r
i
a
c
t
o
m
w
v
C
d
y
w
F
t
c
t
S
c
p
G
t
d
d
d
p
d
c
r
[
m
d
c
f
t
K
m
t
v
g
t
n
v
t
t
c
t
v
d
e
d
e
t
o
(
a
e
w
e
p
p
4
y
f
c
r
r
b
t
t
R
C
i
3
c
t
i
b
p
a
p
m
t
t
6
T
i
s
2
1
(
1
l
i
a
B
3
.
t
g
w
Serious Infections after Unrelated Donor Transplantation
BInfections were classiﬁed by type as bacterial (typ-
cal gram-positive and gram-negative organisms), vi-
al, fungal, pneumonia without an identiﬁed organ-
sm, and an “other” category, which consisted of
typical bacteria and Clostridium difﬁcile. Clinically
ompatible time frames were used to deﬁne 1 infec-
ious episode from a second episode with the same
rganism. For CMV and herpes simplex virus, the
aximum allowed interval for a single infectious event
as 60 days, whereas for herpes-zoster virus and other
iral infections, it was 14 days. For bacteria other than
. difﬁcile, the allowed interval was 7 days (for C.
ifﬁcile it was 31 days). Fourteen days was used for
east infections (Candida and Cryptococcus species),
hereas the allowed interval for molds (Aspergillus,
usarium, and Mucor species) was 90 days. An infec-
ious episode that was clinically improving, but not
ompletely eradicated, by the end of the allowed in-
erval was counted as a single event.
tatistical Analysis
In addition to the analysis of serious infectious
omplications, the conventional transplantation end
oints analyzed included neutrophil recovery, acute
VHD (grades II-IV and III/IV), chronic GVHD,
ransplant-related mortality, survival, and causes of
eath. The event time for neutrophil recovery was the
ate of transplantation to the ﬁrst of 3 consecutive
ays with neutrophil recovery to 0.5  109/L, and
atients without neutrophil recovery by day 42 were
eﬁned as having graft failure. Diagnosis of acute and
hronic GVHD was based on standard clinical crite-
ia, with histopathologic conﬁrmation where possible,
8,9] and the maximal grade of GVHD was deter-
ined by independent review. The cumulative inci-
ence of neutrophil engraftment and acute and
hronic GVHD was calculated by treating deaths
rom other causes as competing risks. [10] The statis-
ical end point of survival was estimated by the
aplan-Meier method. [11]
The major end points of this study were the cu-
ulative incidence of 1 or more serious infections and
he relative risk (RR) of serious infection with multi-
ariate methods. The cumulative incidence distin-
uished patients who had at least 1 serious infection in
he 2 years after transplantation from those who had
one in the 3 patient groups. In contrast, the multi-
ariate technique enabled analysis of all serious infec-
ions within each subject by using a Cox regression–
ype analysis to calculate the RRs. However, the
orrelation of multiple events within each subject was
aken into account by an appropriate correction to the
ariance estimate, and an appropriate risk set was
eﬁned for each infection.
The models that performed this task were the Wei
t al. [12] approach to assess multiple infections of r
B&MTifferent types and the conditional models of Prentice
t al. [13] for multiple infections of a similar type. In
he former model, a patient is always at risk for 1 type
f infection (eg, fungal) even if another infection type
eg, bacterial) has already occurred. In the latter model,
patient is not at risk for a second CMV infection, for
xample, until 60 days after the ﬁrst CMV infection,
ith clinically appropriate intervals incorporated for
ach infection type (as deﬁned previously). These end
oints were evaluated within the 2 years after trans-
lantation overall and within the periods 0 to 42 days,
3 to 100 days, 101 to 180 days, and 181 days to 2
ears. Patients were censored from analysis at graft
ailure or relapse/disease progression. Deaths from
auses other than infection were treated as competing
isks in the estimates of cumulative incidence. The
ates of serious infections were represented pictorially
y the infection density per 1000 patient-days. Event
imes were measured from the date of transplantation
o the date of death or last contact.
ESULTS
umulative Incidence of Serious Infection
Among the 136 patients, there were 363 serious
nfections during the ﬁrst 2 years after transplantation:
20 (88%) were in the severe category, 18 (5%) were
onsidered life-threatening, and 25 (7%) resulted in
he death of the patient (Table 2). Overall, bacterial
nfections were the most frequent (n  208), followed
y viral infections (n 88), fungal infections (n 33),
neumonia without an identiﬁed organism (n  25),
nd infections in the “other” category (n  9). Most
atients had at least 1 serious infection, and the cu-
ulative incidence of 1 or more serious infections for
he entire period was not signiﬁcantly different be-
ween groups: 81% (95% conﬁdence interval [CI],
5%-97%) in BM, 83% (95% CI, 60%-100%) in
CD, and 90% (95% CI, 74%-100%) in UCB recip-
ents (P  .48; Figure 1). The median number of
erious infectious episodes per patient during the
-year period was 2 (range, 1-12) in BM, 3.5 (range,
-18) in TCD, and 2 (range, 1-10) in UCB recipients
P  .12).
Within the periods days 0 to 42, 43 to 100, and
01 to 180, the only signiﬁcant difference in the cumu-
ative incidence of serious infections between groups was
n days 43 to 100, when a greater proportion of TCD
nd UCB recipients had 1 or more serious infections:
M, 35% (95% CI, 21%-49%); TCD, 57% (95% CI,
5%-79%); and UCB, 58% (95% CI, 43%-73%; P 
04). However, during this time period, among pa-
ients with serious infections, the unmanipulated BM
roup had a median of 2 (range, 1-3) per patient,
hereas TCD recipients had 1 (range, 1-4) and UCB
ecipients had 1 (range, 1-4; P  .17).
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3After day 180, the cumulative incidence of serious
nfections was not signiﬁcantly different between
roups: BM, 37% (95% CI, 18%-56%); TCD, 44%
95% CI, 21%-77%); and UCB, 23% (95% CI, 8%-
8%; P  .40). During this period, among patients
ith serious infections, BM recipients had a median of
(range, 1-5) per patient, whereas TCD recipients
able 2. Number of Serious Infection Episodes by Severity and
rganism Type
Variable BM TCD UCB Total
acterial
Severe 70 49 75 194
Life-threatening 3 3 1 7
Fatal 4 1 2 7
Gram positive 36 21 41 98
Staphylococcus 27 15 26 68
Streptococcus 6 4 10 20
Other 3 2 5 10
Gram negative 33 26 24 83
Sinusitis 6 3 10 19
Other 2 3 3 8
Total 77 53 78 208
iral
Severe 21 28 29 78
Life-threatening 1 4 1 6
Fatal 1 1 2 4
CMV* 5 23 13 41
Herpes simplex 4 2 2 8
Herpes zoster 10 6 9 25
RSV 1 1 0 2
Polyomavirus 1 0 2 3
Adenovirus 2 1 5 8
Other 0 0 1 1
Total 23 33 32 88
ungal
Severe 8 6 4 18
Life-threatening 0 2 1 3
Fatal 6 2 4 12
Yeast 8 2 4 14
Candida albicans 1 1 1 3
Non-albicans 4 1 2 7
Yeast (NOS) 3 0 1 4
Aspergillus 6 5 4 15
Other 0 3 1 4
Total 14 10 9 33
ther infections
Severe 1 3 4 8
Life-threatening 1 0 0 1
Fatal 0 0 0 0
Clostridium difficile 0 1 2 3
Mycobacteria 0 2 0 2
Mycoplasma 1 0 2 3
Other 1 0 0 1
Total 2 3 4 9
neumonia†
Severe 7 4 11 22
Life-threatening 1 0 0 1
Fatal 1 0 1 2
Total 9 4 12 25
MV indicates cytomegalovirus; RSV, respiratory syncytial virus;
NOS, not otherwise speciﬁed.
Of the 41 CMV infections, 34 were isolated CMV viremia,
whereas 7 patients had end-organ disease.
The pneumonia category refers to clinical evidence of pneumonia
without an identiﬁed organism. d
66ad 4 (range, 1-14) and UCB recipients had 1 (range,
-2; P  .20).
ultivariate Analysis of the Risk of Serious Infection
To better elucidate the differences in serious in-
ectious complications between the patient groups, the
R of infection was analyzed by taking all serious
nfections for each patient into account by using un-
anipulated BM recipients as the reference group.
verall, in the 2-year posttransplantation period, there
ere no signiﬁcant differences between groups over-
ll: TCD RR, 1.6 (95% CI, 0.9-2.4; P  .10); UCB
R, 1.0 (0.7-1.5; P  .84). However, within infection
ypes, TCD recipients had a greater risk of viral in-
ections than BM recipients: RR, 2.7 (95% CI, 1.5-5.0;
 .01; Figure 2).
Within the periods days 0 to 42, 43 to 100, and
01 to 180, the only signiﬁcant difference between
atient groups was that TCD recipients had signiﬁ-
antly more serious viral infections than unmanipu-
ated BM recipients from days 0 to 42 (RR, 3.5; 95%
I, 1.3-9.9; P  .02; Figure 3). After day 180, as
ompared with BM recipients, TCD recipients had
he most infections overall (RR, 3.1; 95% CI, 1.1-8.2;
igure 1. Cumulative incidence of serious infection: day 0 to 2
ears. In the 2 years after transplantation, there were no signiﬁcant
ifferences in the overall cumulative incidence of 1 or more serious
nfections between transplantation groups. The number of patients
t risk at each time point is indicated below the x-axis for each
atient group.
igure 2. Comparison of serious infection risk: day 0 to 2 years.
CD recipients had signiﬁcantly more serious viral infections than
nmanipulated BM recipients. Otherwise, there were no signiﬁcant
ifferences between groups.
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Serious Infections after Unrelated Donor Transplantation
B .03; Figure 4). This was largely accounted for by
n increased risk of viral infections (RR, 20.0; 95% CI,
.5-164; P  .01), whereas the RR for bacterial infec-
ions in these patients was 2.0 (95% CI, 0.6-6.7; P 
26) and for fungal infections was 4.0 (95% CI, 0.8-20;
 .10). In contrast, as compared with unmanipu-
ated BM, UCB recipients had an overall RR of 0.5
95% CI, 0.2-1.5; P  .23) during this late time
eriod.
ffect of Neutrophil Engraftment on Serious
nfection Risk
Recipients of TCD recovered neutrophils signiﬁ-
antly faster (14.5 days; range, 11-23 days), with no
ifferences between BM (23 days; range, 15-30 days)
nd UCB (22 days; range, 9-54 days) recipients (P 
01). However, the cumulative incidence of neutrophil
ngraftment at day 42 was equivalent between groups:
M, 94% (95% CI, 87%-100%); TCD, 92% (95%
I, 81%-100%); and UCB, 91% (95% CI, 84%-98%;
 .80). Overall, regardless of HSC source, the
nfection risk in the ﬁrst 42 days was signiﬁcantly
ncreased in patients who had graft failure (RR, 3.0;
5% CI, 1.3-7.0; P  .01) as compared with patients
ho engrafted by day 42. However, if the analysis was
estricted to engrafting patients only, the speed of
eutrophil recovery did not affect the serious infection
isk in the ﬁrst 42 days after transplantation. By using
he patients who recovered neutrophils between days
and 14 as the reference group, the RR of infection
or patients recovering between days 15 and 20, 21
nd 27, and 28 and 42 was 1.3 (95% CI, 0.7-2.6), 1.3
95% CI, 0.7-2.2), and 0.9 (95% CI, 0.5-1.9), respec-
ively (P  .80).
ffect of Acute GVHD on Serious Infection Risk
UCB recipients had signiﬁcantly less grade II to
V acute GVHD: BM, 60% (95% CI, 45%-75%);
CD, 42% (95% CI, 22%-62%); and UCB, 32%
95% CI, 20%-44%; P  .01). Also, HLA disparity
onferred a lesser risk of grade II to IV acute GVHD
igure 3. Comparison of serious infection risk: days 0 to 42. TCD
ecipients had signiﬁcantly more serious viral infections than un-
anipulated BM recipients. Otherwise, there were no signiﬁcant
ifferences between groups.n recipients of mismatched UCB as compared with r
B&MTismatched BM: 5/6 matched BM, 75% (95% CI,
1%-99%); 5/6 matched TCD, 43% (95% CI, 8%-
2%); and 4/6 matched UCB, 31% (95% CI, 14%-
8%; P  .01). Although UCB recipients also had a
ow incidence of grade III/IV acute GVHD (BM:
5%; 95% CI, 13%-37%; TCD: 21%; 95% CI, 5%-
7%; UCB: 12%; 95% CI, 4%-20%; P  .20) and
hronic GVHD (BM: 21%; 95% CI, 11%-31%;
CD: 29%; 95% CI, 11%-47%; UCB: 8%; 95% CI,
%-15%; P  .20), these differences did not reach
igniﬁcance. Multiple regression analysis revealed that
rade III/IV acute GVHD was associated with an RR
f serious infection in the 2 years after transplantation
f 1.7 (1.1-2.6; P  .02; Table 3). The effect of grade
II/IV acute GVHD was assessed within each donor
ype, and this assessment revealed that severe acute
VHD had an adverse effect on the infection risk
egardless of donor type (Table 3).
ffect of HSC Source and HLA Disparity on
erious Infection Risk
In the multiple regression analysis, both HLA
isparity and HSC source were analyzed (Table 3). It
s interesting to note that HLA disparity was associ-
ted with an increased risk of infection in 5/6 TCD
ecipients (RR, 3.2; 95% CI, 1.9-5.8; P .01), but not
n 4/6 UCB recipients (RR, 1.2; 95% CI, 0.8-2.0; P 
34). Recipients of 5/6 unmanipulated BM had a RR of
.5 (95% CI, 0.9-2.4; P  .16).
ther Factors Associated with Serious
nfection Risk
Regression analysis also showed that age 8 years
as signiﬁcantly associated with an increased infection
isk (Table 3), whereas diagnosis, transplantation year,
nd season were not. Positive recipient CMV status
as associated with an RR of serious infection of 1.3
95% CI, 0.9-2.0; P .13). A separate analysis of graft
ell dose did not show any effect on infection risk for
ny of the 3 transplantation groups (data not shown).
igure 4. Comparison of serious infection risk: day 181 to 2 years.
fter 6 months, TCD recipients had a signiﬁcantly greater risk of
erious infections, whereas the risk of UCB recipients was compa-
able to that of unmanipulated BM recipients.
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3ransplant-Related Mortality, Survival, and
ontribution of Serious Infection to Death
Despite the increased risk of serious infections in
CD recipients, this did not adversely affect the sur-
ival of these patients. In fact, there was a trend to-
ard increased day 180 transplant-related mortality in
M recipients: BM, 31% (95% CI, 18%-44%); TCD,
% (95% CI, 0%-19%); and UCB, 17% (95% CI,
%-26%; P  .06). However, 2-year survival (BM:
5%; 95% CI, 31%-59%; TCD: 63%; 95% CI, 43%-
3%; UCB: 43%; 95% CI, 29%-57%; P  .29) was
ot signiﬁcantly different between groups. In addi-
ion, the proportion of patients within each group who
ad infection as either causal or contributory to their
eath (BM, 36%; TCD, 33%; and UCB, 30%) was
ot different.
ISCUSSION
Because there have been no randomized studies of
RD UCBT versus BMT, how infection risk after
CBT compares to that after URD BMT is not
nown. Several studies have reported a high incidence
f fatal infection after UCBT. [4,14,15] Furthermore,
able 3. Multiple Regression Analyses of Serious Infection Risk: Day 0
o 2 Years
Variable RR P Value
actors associated with serious
infection*
Age (y)
<8 1.0
>8 1.4 (1.0-1.9) .04
Donor
6/6 BM 1.0
5/6 BM† 1.5 (0.9-2.4) .16
6/6 TCD 1.2 (0.6-2.2) .64
5/6 TCD‡ 3.2 (1.9-5.8) <.01
5-6/6 UCB 1.3 (0.8-2.0) .28
4/6 UCB 1.2 (0.8-2.0) .34
Grade III/IV acute GVHD
No 1.0
Yes 1.7 (1.1-2.6) .02
ffect of acute GVHD grade III/IV§
BM no GVHD 1.0
BM with GVHD 1.8 (1.0-3.5) .06
TCD no GVHD 1.5 (0.9-2.6) .12
TCD with GVHD 2.2 (0.9-5.6) .08
UCB no GVHD 1.1 (0.8-4.3) .63
UCB with GVHD 1.9 (1.0-3.8) .05
Factors included in the regression model were age, sex, diagnosis
(acute lymphoblastic leukemia versus other diagnoses), recipient
cytomegalovirus serostatus, year of transplantation, season (winter
[November through April] versus summer [May through Octo-
ber]), donor type, HLA match, and time-dependent GVHD.
Includes two 4/6 matched BM recipients.
Includes one 4/6 matched TCD recipient.
Assessed within each donor type by using unmanipulated BM
without grade III/IV acute GVHD as the reference.n a retrospective comparison of the outcomes of o
68RD BMT and UCBT in children with leukemia,
ocha et al. [16] reported delayed hematopoietic re-
overy and increased day 100 transplant-related mor-
ality in recipients of UCBT as compared with unma-
ipulated BMT, and a substantial proportion of early
eaths were related to infection in UCBT recipients.
owever, although infection risk after UCBT may be
igniﬁcant, the assessment of infection risk in retro-
pective studies may be complicated by the fact that
arly experience in UCBT has included a signiﬁcant
roportion of high-risk patients, and the potential
isproportionate representation of high-risk patients
mong UCB recipients may be exacerbated by the
apid availability of UCB as compared with volunteer
M. [17]
In contrast to these clinical reports, studies of
mmune reconstitution after UCBT, although rela-
ively small, have demonstrated recovery comparable
o that seen after BMT. [18-20] Moretta et al. [21]
ound a marked increase in the number of B lympho-
ytes, superior recovery of CD4 T lymphocytes, and
omparable recovery of CD3 and CD8 T cells and
atural killer cells in children receiving UCB as com-
ared with those receiving BM. Klein et al. [22] have
emonstrated T-cell recovery within 6 to 12 months
n pediatric recipients of UCBT, with normal levels of
-cell receptor excision circles (TREC) starting at 12
onths after transplantation. Weinberg et al. [23]
ave shown that GVHD is the most important pre-
ictor of thymic recovery after HSC transplantation.
his could favor recipients of UCBT. Indeed, these
uthors found TREC levels in UCB recipients com-
arable to those of BM recipients and documented
hat in the absence of GVHD, TREC levels increased
espite ongoing immunosuppression.
To investigate infection risk, we studied the serious
nfectious complications after pediatric URD HSC
ransplantation and used multivariate analysis tech-
iques to take all infections into account. Although
he UCB patients in this study had shorter follow-up
han the BMT and TCD recipients, as shown in Fig-
re 1, the validity of the comparison is substantiated
y the signiﬁcant numbers of survivors in each of the
groups throughout the 2-year posttransplantation
eriod. This retrospective study has the potential lim-
tation that differences in patient characteristics, pre-
arative regimens, immune suppression, or supportive
are could contribute to the observed outcome. Also,
ecause all TCD patients underwent marrow TCD by
lutriation, the outcome of these patients may not
eﬂect the outcome of patients receiving TCD by
ther methods. However, this study has the advantage
f being from a single institution that offers a uniform
pproach to patient care and has uniform policy with
egard to long-term follow-up for all patients. Al-
hough differences in supportive care over time have
ccurred, this should not have substantially con-
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Serious Infections after Unrelated Donor Transplantation
Bounded the results. For example, because both CMV
isease and CMV antigenemia were classiﬁed as seri-
us infections, CMV infection should not be overrep-
esented in the patients who underwent transplanta-
ion in the earlier time period. In fact, given the more
ntensive surveillance for CMV reactivation in the
ater period of this study, CMV could be overrepre-
ented in these patients relative to the earlier patients
ecause of better detection. In addition, changes in
rophylaxis (ganciclovir versus acyclovir) have not
een shown to affect the incidence of CMV infection
t our institution. [24] Also, the study period was
efore the routine use of the new antifungal agents,
uch as the extended-spectrum azoles and the echino-
andins.
This study demonstrates that serious infection is a
ajor complication of URD transplantation regard-
ess of HSC source. Although UCBT and TCD re-
ipients had a higher cumulative incidence of 1 or
ore serious infections from days 43 to 100 than
nmanipulated BM recipients, the RR of serious in-
ection in UCB recipients was not increased when all
nfections were taken into account, and after 6 months,
he risk associated with UCBT was signiﬁcantly less
han that with TCD. Finally, the proportion of pa-
ients who had infection as either causal or contribu-
ory to their death was not different between groups.
Therefore, the suggestion that UCBT is associ-
ted with an increased infection risk as compared with
ther URD HSC sources is not supported by this
nalysis. There are a number of potential explanations
or this observation. First, neutrophil recovery after
CBT was not prolonged as compared with unma-
ipulated BMT. In addition, the analysis of the effect
f engraftment on early infection risk showed that
raft failure, but not slow neutrophil recovery, in-
reased serious infection risk. Therefore, UCBT re-
ipients would not have been disadvantaged, because
hey had an incidence of engraftment comparable to
hat of BMT recipients. The analysis of the effect of
rade III/IV acute GVHD showed that this had an
dverse effect regardless of the HSC source. However,
CBT recipients would have beneﬁted from having
he lowest incidence of acute GVHD. Small patient
umbers precluded a similar analysis as to the effect of
hronic GVHD, but it is possible that the low inci-
ence of chronic GVHD in UCBT recipients would
lso have been advantageous.
Finally, HLA disparity seemed to have a differen-
ial effect depending on the HSC source and was
ssociated with a 1.5 times increased infection risk
fter 5/6 unmanipulated BMT, a 3.2 times increased
isk after 5/6 TCD, and only a 1.2 times increased risk
fter 4/6 UCBT. A lack of signiﬁcant numbers of
ecipients of 6/6 UCB precludes a statement about the
ole of HLA disparity in infection risk after UCBT.
owever, this study suggests that HLA disparity may
B&MTot be as deleterious to immune recovery after UCBT
s compared with BMT. This ﬁnding may be at least
artially explained by the less frequent incidence of
cute GVHD in recipients of 4/6 UCB as compared
ith mismatched BM.
Only a large randomized study controlling for
atient and graft characteristics and supportive care
ould deﬁnitively address how infection risk compares
ith each HSC source. Further, to fully understand
mmune recovery after transplantation, studies are
eeded that correlate the clinical data of infectious
omplications with concurrent laboratory measures of
mmune reconstitution. Until such data are available,
his study suggests that the risk of serious infection
fter pediatric UCBT and unmanipulated BMT is
imilar. Further, the differences in infection risk after
months in UCBT and TCD recipients suggest there
re signiﬁcant differences in immune recovery with
hese HSC sources at this late time point. This is
onsistent with the kinetics of T-cell recovery after
ediatric UCBT reported by Klein et al. [22]
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